Research to cost-effectiveness of paricalcitol of the treatment of secundary hyperparathyroidism at hemodialysis patients
- Conditions
- Chronic Renal Failure: chronisch nierfalenSecondary Hyperparathyroidism: secundaire hyperparathyreoidieVitamin D: vitamine DParicalcitol: paricalcitol
- Registration Number
- NL-OMON24822
- Lead Sponsor
- Sint Lucas Andreas ziekenhuis
- Brief Summary
/A
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 114
Inclusion Criteria
1. Hemodialysis patients older than 18 years
2. Secundary hyperparathyroidism
Exclusion Criteria
1. Severe hypercalcemia
2. Severe liver failure
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Effectiveness: measure the main PTH level<br><br>
- Secondary Outcome Measures
Name Time Method Security<br /><br>Main Calcium (Ca2+)-level<br /><br>Main Fosfaat (P)-level<br /><br>Main Calicum-Fosfaatproduct (Ca x P) -level<br /><br>Numbers of hypercalcemia episodes <br /><br>Numbers of hyperphosphatemia episodes<br /><br>Numbers of raised Ca x P episodes <br /><br>Bone-alkaline phosphatase (BAP), expressed as a Z-score<br /><br><br /><br /><br>Costs<br /><br>Total costs of the whole treatment: <br />measuring the oral medication of phosphate-binders and calcimimetics.<br><br>